NR3C2 and diabetes mellitus: The ARTS-HF phase 2b trial (Mineralocorticoid Receptor antagonist Tolerability Study-HF) compared the efficacy of finerenone vs. eplerenone in patients with HfrEF and diabetes or chronic kidney disease, showing similar reduction effects on natriuretic peptide with a greater safety profile [297].